nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—AKR1B1—forebrain—attention deficit hyperactivity disorder	0.034	0.0686	CbGeAlD
Sulindac—PTGDR2—cerebellum—attention deficit hyperactivity disorder	0.0327	0.0659	CbGeAlD
Sulindac—AKR1B1—cardiovascular system—attention deficit hyperactivity disorder	0.0287	0.058	CbGeAlD
Sulindac—PPARD—forebrain—attention deficit hyperactivity disorder	0.0267	0.0539	CbGeAlD
Sulindac—PTGDR2—brain—attention deficit hyperactivity disorder	0.0265	0.0536	CbGeAlD
Sulindac—MAPK3—forebrain—attention deficit hyperactivity disorder	0.0246	0.0497	CbGeAlD
Sulindac—AKR1B1—midbrain—attention deficit hyperactivity disorder	0.0224	0.0453	CbGeAlD
Sulindac—MAPK3—cardiovascular system—attention deficit hyperactivity disorder	0.0208	0.042	CbGeAlD
Sulindac—AKR1B1—nervous system—attention deficit hyperactivity disorder	0.0185	0.0372	CbGeAlD
Sulindac—AKR1B1—central nervous system—attention deficit hyperactivity disorder	0.0178	0.0359	CbGeAlD
Sulindac—PPARD—midbrain—attention deficit hyperactivity disorder	0.0177	0.0356	CbGeAlD
Sulindac—AKR1B1—cerebellum—attention deficit hyperactivity disorder	0.0174	0.035	CbGeAlD
Sulindac—MAPK3—midbrain—attention deficit hyperactivity disorder	0.0163	0.0328	CbGeAlD
Sulindac—PPARD—nervous system—attention deficit hyperactivity disorder	0.0145	0.0293	CbGeAlD
Sulindac—AKR1B1—brain—attention deficit hyperactivity disorder	0.0141	0.0285	CbGeAlD
Sulindac—PPARD—central nervous system—attention deficit hyperactivity disorder	0.014	0.0282	CbGeAlD
Sulindac—PPARD—cerebellum—attention deficit hyperactivity disorder	0.0137	0.0276	CbGeAlD
Sulindac—MAPK3—nervous system—attention deficit hyperactivity disorder	0.0134	0.027	CbGeAlD
Sulindac—MAPK3—central nervous system—attention deficit hyperactivity disorder	0.0129	0.026	CbGeAlD
Sulindac—MAPK3—cerebellum—attention deficit hyperactivity disorder	0.0126	0.0254	CbGeAlD
Sulindac—PPARD—brain—attention deficit hyperactivity disorder	0.0111	0.0224	CbGeAlD
Sulindac—MAPK3—brain—attention deficit hyperactivity disorder	0.0102	0.0206	CbGeAlD
Sulindac—SLC22A6—brain—attention deficit hyperactivity disorder	0.00782	0.0158	CbGeAlD
Sulindac—PTGS1—forebrain—attention deficit hyperactivity disorder	0.0067	0.0135	CbGeAlD
Sulindac—PTGS2—forebrain—attention deficit hyperactivity disorder	0.0064	0.0129	CbGeAlD
Sulindac—PTGS1—cardiovascular system—attention deficit hyperactivity disorder	0.00566	0.0114	CbGeAlD
Sulindac—PTGS2—cardiovascular system—attention deficit hyperactivity disorder	0.00541	0.0109	CbGeAlD
Sulindac—ALB—brain—attention deficit hyperactivity disorder	0.00488	0.00984	CbGeAlD
Sulindac—PTGS2—midbrain—attention deficit hyperactivity disorder	0.00423	0.00853	CbGeAlD
Sulindac—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.00414	0.00835	CbGeAlD
Sulindac—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.00398	0.00804	CbGeAlD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00386	0.00764	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00379	0.00751	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00374	0.00742	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00373	0.00739	CbGpPWpGaD
Sulindac—PPARD—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00367	0.00728	CbGpPWpGaD
Sulindac—PTGS1—nervous system—attention deficit hyperactivity disorder	0.00363	0.00734	CbGeAlD
Sulindac—PTGS1—central nervous system—attention deficit hyperactivity disorder	0.0035	0.00706	CbGeAlD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00349	0.00691	CbGpPWpGaD
Sulindac—PTGS2—nervous system—attention deficit hyperactivity disorder	0.00347	0.00701	CbGeAlD
Sulindac—MAPK3—RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription—POLR3A—attention deficit hyperactivity disorder	0.00344	0.00681	CbGpPWpGaD
Sulindac—PTGS2—central nervous system—attention deficit hyperactivity disorder	0.00334	0.00675	CbGeAlD
Sulindac—PTGS2—cerebellum—attention deficit hyperactivity disorder	0.00327	0.0066	CbGeAlD
Sulindac—PTGDR2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00326	0.00646	CbGpPWpGaD
Sulindac—CYP1A1—brain—attention deficit hyperactivity disorder	0.00316	0.00638	CbGeAlD
Sulindac—SLC22A6—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00314	0.00623	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.0031	0.00615	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00309	0.00613	CbGpPWpGaD
Sulindac—MAPK3—Neurotrophic factor-mediated Trk receptor signaling—BDNF—attention deficit hyperactivity disorder	0.00307	0.00608	CbGpPWpGaD
Sulindac—CYP1A1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00304	0.00603	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00304	0.00603	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00303	0.00601	CbGpPWpGaD
Sulindac—CYP1A1—Oxidative Stress—MAOA—attention deficit hyperactivity disorder	0.00296	0.00587	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00294	0.00582	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00289	0.00572	CbGpPWpGaD
Sulindac—CYP1A2—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00286	0.00567	CbGpPWpGaD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00285	0.00565	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00285	0.00565	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00282	0.00559	CbGpPWpGaD
Sulindac—PTGS1—brain—attention deficit hyperactivity disorder	0.00278	0.00561	CbGeAlD
Sulindac—PTGDR2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00276	0.00547	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00274	0.00542	CbGpPWpGaD
Sulindac—PTGS2—brain—attention deficit hyperactivity disorder	0.00266	0.00536	CbGeAlD
Sulindac—PTGDR2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00266	0.00526	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00258	0.00512	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00248	0.00492	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00244	0.00484	CbGpPWpGaD
Sulindac—MAPK3—Retinoic acid receptors-mediated signaling—EP300—attention deficit hyperactivity disorder	0.00242	0.0048	CbGpPWpGaD
Sulindac—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.00241	0.00477	CbGpPWpGaD
Sulindac—MAPK3—Transcription—POLR3A—attention deficit hyperactivity disorder	0.00233	0.00462	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00214	0.00424	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00213	0.00423	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00213	0.00423	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00211	0.00418	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.0021	0.00416	CbGpPWpGaD
Sulindac—MAPK3—Cellular response to heat stress—EP300—attention deficit hyperactivity disorder	0.00201	0.00398	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00197	0.00391	CbGpPWpGaD
Sulindac—PTGS1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00196	0.00388	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00195	0.00387	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00195	0.00387	CbGpPWpGaD
Sulindac—CYP1A2—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00194	0.00385	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00194	0.00384	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00191	0.00379	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00186	0.00369	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00184	0.00365	CbGpPWpGaD
Sulindac—MAPK3—IFN-gamma pathway—EP300—attention deficit hyperactivity disorder	0.00182	0.0036	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00181	0.00359	CbGpPWpGaD
Sulindac—PPARD—Wnt Signaling Pathway and Pluripotency—EP300—attention deficit hyperactivity disorder	0.00178	0.00353	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00171	0.0034	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00171	0.00338	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00167	0.00332	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00167	0.0033	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00166	0.00329	CbGpPWpGaD
Sulindac—ALB—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00163	0.00324	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00163	0.00323	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00163	0.00323	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00162	0.00322	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00161	0.00319	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.0016	0.00317	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.0016	0.00316	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00156	0.00308	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00154	0.00306	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00153	0.00302	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00152	0.00302	CbGpPWpGaD
Sulindac—MAPK3—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.00151	0.003	CbGpPWpGaD
Sulindac—MAPK3—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—attention deficit hyperactivity disorder	0.00151	0.003	CbGpPWpGaD
Sulindac—MAPK3—IL-4 Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00151	0.003	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00151	0.00299	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.0015	0.00297	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00148	0.00294	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00146	0.0029	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—SYNE1—attention deficit hyperactivity disorder	0.00146	0.0029	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00144	0.00285	CbGpPWpGaD
Sulindac—MAPK3—Kit receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.00141	0.0028	CbGpPWpGaD
Sulindac—MAPK3—ATF-2 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00141	0.0028	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00141	0.00279	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00141	0.00279	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00139	0.00276	CbGpPWpGaD
Sulindac—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00138	0.00273	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00136	0.0027	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00136	0.0027	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00132	0.00261	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—COMT—attention deficit hyperactivity disorder	0.00129	0.00256	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00128	0.00254	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00127	0.00252	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—POLR3A—attention deficit hyperactivity disorder	0.00127	0.00252	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00124	0.00247	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00123	0.00244	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00121	0.00239	CbGpPWpGaD
Sulindac—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.00113	0.00224	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00113	0.00224	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00112	0.00222	CbGpPWpGaD
Sulindac—PPARD—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00222	CbGpPWpGaD
Sulindac—SLC22A6—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00109	0.00217	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—EP300—attention deficit hyperactivity disorder	0.00108	0.00215	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—EP300—attention deficit hyperactivity disorder	0.00108	0.00215	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00108	0.00213	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00105	0.00208	CbGpPWpGaD
Sulindac—PTGS1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00105	0.00208	CbGpPWpGaD
Sulindac—PTGS1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00104	0.00206	CbGpPWpGaD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00102	0.00203	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000992	0.00197	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000989	0.00196	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000954	0.00189	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000946	0.00188	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000919	0.00182	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000909	0.0018	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000909	0.0018	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000907	0.0018	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00089	0.00176	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MB21D1—attention deficit hyperactivity disorder	0.000888	0.00176	CbGpPWpGaD
Sulindac—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000879	0.00174	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000875	0.00173	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000864	0.00171	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STUB1—attention deficit hyperactivity disorder	0.00086	0.00171	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00083	0.00164	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000809	0.0016	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000805	0.0016	CbGpPWpGaD
Sulindac—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000804	0.00159	CbGpPWpGaD
Sulindac—MAPK3—Disease—STUB1—attention deficit hyperactivity disorder	0.000794	0.00157	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000793	0.00157	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000792	0.00157	CbGpPWpGaD
Sulindac—PPARD—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000773	0.00153	CbGpPWpGaD
Sulindac—PPARD—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000773	0.00153	CbGpPWpGaD
Sulindac—PPARD—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00076	0.00151	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000741	0.00147	CbGpPWpGaD
Sulindac—CYP1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000738	0.00146	CbGpPWpGaD
Sulindac—CYP1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000733	0.00145	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000732	0.00145	CbGpPWpGaD
Sulindac—CYP1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000728	0.00144	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000713	0.00141	CbGpPWpGaD
Sulindac—PPARD—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000707	0.0014	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.000691	0.00137	CbGpPWpGaD
Sulindac—ALB—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000678	0.00134	CbGpPWpGaD
Sulindac—MAPK3—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000652	0.00129	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—POLR3A—attention deficit hyperactivity disorder	0.000648	0.00129	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—EP300—attention deficit hyperactivity disorder	0.000632	0.00125	CbGpPWpGaD
Sulindac—PPARD—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000618	0.00122	CbGpPWpGaD
Sulindac—PPARD—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000588	0.00117	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000579	0.00115	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000579	0.00115	CbGpPWpGaD
Sulindac—ALB—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000568	0.00113	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000564	0.00112	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000556	0.0011	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000556	0.0011	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000554	0.0011	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000551	0.00109	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000549	0.00109	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00048	0.000952	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000478	0.000947	CbGpPWpGaD
Sulindac—PTGS2—Disease—STUB1—attention deficit hyperactivity disorder	0.000472	0.000936	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00047	0.000932	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000468	0.000928	CbGpPWpGaD
Sulindac—PPARD—Metabolism—COMT—attention deficit hyperactivity disorder	0.000468	0.000928	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000467	0.000926	CbGpPWpGaD
Sulindac—PPARD—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000465	0.000921	CbGpPWpGaD
Sulindac—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000464	0.00092	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000459	0.00091	CbGpPWpGaD
Sulindac—CYP1A1—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000452	0.000897	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000451	0.000894	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000446	0.000885	CbGpPWpGaD
Sulindac—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000443	0.000878	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000432	0.000857	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000428	0.000849	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000425	0.000843	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000425	0.000842	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00042	0.000832	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000391	0.000775	CbGpPWpGaD
Sulindac—MAPK3—Disease—SNAP25—attention deficit hyperactivity disorder	0.000377	0.000747	CbGpPWpGaD
Sulindac—ALB—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000356	0.000706	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00034	0.000674	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000328	0.00065	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000325	0.000643	CbGpPWpGaD
Sulindac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000305	0.000605	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000302	0.000598	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000299	0.000592	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000296	0.000586	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000296	0.000586	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000291	0.000576	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000289	0.000572	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000284	0.000562	CbGpPWpGaD
Sulindac—ALB—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000275	0.000545	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000274	0.000543	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00027	0.000536	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000267	0.000529	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000264	0.000523	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000258	0.000511	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000255	0.000506	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000253	0.000501	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000251	0.000498	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000248	0.000492	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000239	0.000473	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000236	0.000468	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000235	0.000465	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000235	0.000465	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000231	0.000458	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000231	0.000458	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000228	0.000451	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000225	0.000446	CbGpPWpGaD
Sulindac—PTGS2—Disease—SNAP25—attention deficit hyperactivity disorder	0.000224	0.000444	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000215	0.000425	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000208	0.000413	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000208	0.000413	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000205	0.000406	CbGpPWpGaD
Sulindac—PPARD—Metabolism—EP300—attention deficit hyperactivity disorder	0.000201	0.000398	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000192	0.000381	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00019	0.000378	CbGpPWpGaD
Sulindac—ALB—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00019	0.000376	CbGpPWpGaD
Sulindac—ALB—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00019	0.000376	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000188	0.000372	CbGpPWpGaD
Sulindac—ALB—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000187	0.00037	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000179	0.000355	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000179	0.000354	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000178	0.000352	CbGpPWpGaD
Sulindac—ALB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000174	0.000344	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000172	0.000342	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000166	0.00033	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000162	0.000321	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000158	0.000314	CbGpPWpGaD
Sulindac—ALB—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000152	0.000301	CbGpPWpGaD
Sulindac—ALB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000144	0.000286	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000142	0.000282	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000141	0.00028	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000137	0.000271	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000133	0.000263	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000133	0.000263	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EP300—attention deficit hyperactivity disorder	0.000133	0.000263	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000131	0.000259	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000126	0.00025	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000125	0.000248	CbGpPWpGaD
Sulindac—MAPK3—Disease—EP300—attention deficit hyperactivity disorder	0.000122	0.000243	CbGpPWpGaD
Sulindac—ALB—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000122	0.000241	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000121	0.000241	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000121	0.000241	CbGpPWpGaD
Sulindac—ALB—Metabolism—COMT—attention deficit hyperactivity disorder	0.000115	0.000228	CbGpPWpGaD
Sulindac—ALB—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000114	0.000226	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000111	0.00022	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000106	0.00021	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000101	0.0002	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.57e-05	0.00017	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	8.04e-05	0.000159	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	7.99e-05	0.000158	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	7.75e-05	0.000154	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—EP300—attention deficit hyperactivity disorder	7.68e-05	0.000152	CbGpPWpGaD
Sulindac—PTGS2—Disease—EP300—attention deficit hyperactivity disorder	7.28e-05	0.000144	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—EP300—attention deficit hyperactivity disorder	6.1e-05	0.000121	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	5.41e-05	0.000107	CbGpPWpGaD
Sulindac—ALB—Metabolism—EP300—attention deficit hyperactivity disorder	4.93e-05	9.78e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	3.45e-05	6.84e-05	CbGpPWpGaD
